IL-1 receptor antagonist (IL-1Ra) fusion protein that binds to the extracellular matrix

JP7863335B2Active Publication Date: 2026-05-21MONASH UNIV
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Filing Date
2021-06-11
Publication Date
2026-05-21

AI Technical Summary

Technical Problem

Existing IL-1Ra compositions face challenges with stability, half-life, and precise localization and retention at the site of action, leading to inefficiencies in treating IL-1 receptor-mediated conditions.

Method used

A fusion protein comprising IL-1Ra and an extracellular matrix-binding peptide, such as PIGF, is developed to enhance binding affinity and controlled release, allowing for prolonged retention and targeted delivery.

Benefits of technology

The fusion protein exhibits significantly improved retention and activity at the site of action, promoting enhanced wound healing and bone regeneration by modulating macrophage polarization and growth factor signaling.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007863335000009
    Figure 0007863335000009
  • Figure 0007863335000010
    Figure 0007863335000010
  • Figure 0007863335000011
    Figure 0007863335000011
Patent Text Reader

Abstract

The present invention provides fusion proteins comprising an interleukin-1 receptor antagonist (IL-1Ra) and an extracellular matrix (ECM)-binding peptide that specifically binds to one or more or all of the extracellular matrix proteins selected from the group consisting of fibrinogen, fibronectin, vitronectin, tenascin-C, and heparan sulfate, and uses of the fusion proteins to treat conditions in which IL-1Ra administration is beneficial or in which IL-1Ra signaling needs to be attenuated, to enhance tissue regeneration, in particular bone regeneration and / or wound repair, or to treat wounds, burns, and disorders of muscle, cartilage, tendon, and bone, to enhance the regenerative activity of growth factor administration, or to reduce inflammation or hyposensitivity of cells to growth factor stimulation.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Particulate formulation for delivery to the lower and central airways, and method for manufacturing it.

    JP2015527310A

  • Tethered protein-based drugs containing an anchor domain for use on the ocular surface - Patent Application 20070122999

    JP2020501510A

  • Methods of producing and purifying matrix-binding fusion proteins by ion-exchange chromatography

    WO2017083491A2